Form D · Biotechnology
Carmenta Bioscience, Inc.
Palo Alto, CA · CIK 0001582250
Offering snapshot reported Jul 30, 2013 · SEC filing
- Reported sold
- $586K Offering amount: $1.88M
- Investors reported
- 25 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 17, 2013 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 30, 2013 | Initial | $585,866 | No comparison | 25 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-200422
Series A Preferred Stock
Source: Form D, filed Jul 30, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Atul Butte | Director |
| Matthew Cooper | Director, Executive |
| Bruce Ling | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4240 Wilkie Way
Palo Alto, CA, 94306
Palo Alto, CA, 94306